These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 21332242)

  • 1. A benefit-risk assessment of erlotinib in non-small-cell lung cancer and pancreatic cancer.
    Mountzios G; Syrigos KN
    Drug Saf; 2011 Mar; 34(3):175-86. PubMed ID: 21332242
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.
    Fuster LM; Sandler AB
    Clin Lung Cancer; 2004 Dec; 6 Suppl 1():S24-9. PubMed ID: 15638954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
    Cohen MH; Johnson JR; Chattopadhyay S; Tang S; Justice R; Sridhara R; Pazdur R
    Oncologist; 2010; 15(12):1344-51. PubMed ID: 21148614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.
    Engle JA; Kolesar JM
    Am J Health Syst Pharm; 2014 Nov; 71(22):1933-8. PubMed ID: 25349236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib: a new therapeutic approach for non-small cell lung cancer.
    Bonomi P
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1395-401. PubMed ID: 12882624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
    Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
    Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of erlotinib in the treatment of non-small cell lung cancer: clinical outcomes in wild-type epidermal growth factor receptor patients.
    Piperdi B; Perez-Soler R
    Drugs; 2012 Jun; 72 Suppl 1(0 1):11-9. PubMed ID: 22712793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Erlotinib in the treatment of non-small cell lung cancer].
    Ostoros G; Döme B
    Magy Onkol; 2006; 50(3):237-41. PubMed ID: 17099784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of erlotinib and its clinical use.
    Tang PA; Tsao MS; Moore MJ
    Expert Opin Pharmacother; 2006 Feb; 7(2):177-93. PubMed ID: 16433583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib in cancer treatment.
    Bareschino MA; Schettino C; Troiani T; Martinelli E; Morgillo F; Ciardiello F
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi35-41. PubMed ID: 17591829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR pathway in advanced non-small cell lung cancer.
    Merlo V; Longo M; Novello S; Scagliotti GV
    Front Biosci (Schol Ed); 2011 Jan; 3(2):501-17. PubMed ID: 21196393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
    Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
    Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.